Edgewise Therapeutics, Inc. (EWTX) Stock Price & How to Invest
Short answer
EWTX is Edgewise Therapeutics, a clinical-stage biotech betting on muscle-targeted small molecules for muscular dystrophy and heart disease, so investing in it means underwriting binary trial readouts rather than current profits. It is a pre-revenue name whose value rests almost entirely on its pipeline and its roughly $500 million cash cushion.
EWTX stock price
As of 2026-07-08, Edgewise Therapeutics, Inc. (EWTX) last closed at $46.30, up 228.6% over the past year. Over the past 52 weeks it has traded between $12.68 and $46.30.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Edgewise Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Edgewise Therapeutics, Inc. (EWTX) do?
Edgewise Therapeutics (Nasdaq: EWTX) is a Boulder, Colorado clinical-stage biopharmaceutical company developing orally administered small molecules that target muscle for rare neuromuscular and serious cardiac conditions. Its lead candidate, sevasemten (formerly EDG-5506), is a skeletal myosin inhibitor in late-stage trials for Becker and Duchenne muscular dystrophy, with the global pivotal GRAND CANYON cohort in Becker due to read out top-line results in the fourth quarter of 2026 and a planned FDA New Drug Application submission in the first half of 2027. A second program, EDG-7500, is a cardiac sarcomere modulator that posted positive 12-week Phase 2 CIRRUS-HCM data in obstructive and nonobstructive hypertrophic cardiomyopathy in mid-2026, with a Phase 3 program targeted to begin in the second half of 2026.
As a pre-commercial company, Edgewise generates no product revenue and runs a steady net loss funded by its balance sheet, reporting roughly $499.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 against a quarterly R&D spend near $42.7 million. The investment picture is a classic clinical-biotech setup: a large market capitalization (around $4.5 billion in mid-2026) built on the expected value of two myosin-modulation programs, a multi-year cash runway, and a share price that tends to move sharply on individual trial readouts. Ownership is a wager on data and eventual regulatory approval rather than on any existing financial results.
What's driving Edgewise Therapeutics, Inc. (EWTX)?
1. Sevasemten in Becker muscular dystrophy
The lead asset is a first-in-class skeletal myosin inhibitor aimed at slowing muscle degeneration in Becker patients, a population with no approved disease-modifying therapy. Long-term extension data have shown functional stabilization out to roughly 3.5 years, and the pivotal GRAND CANYON top-line readout is expected in Q4 2026 with an NDA planned for the first half of 2027. A positive result would be the single largest value catalyst for the company.
2. EDG-7500 in hypertrophic cardiomyopathy
EDG-7500 is a cardiac sarcomere modulator designed to reduce outflow obstruction while limiting the drop in heart pumping function that has dogged the first-generation cardiac myosin inhibitors. Positive 12-week Phase 2 CIRRUS-HCM data in mid-2026 showed gradient and biomarker improvements with no readings of ejection fraction below 50 percent. A Phase 3 program targeted for the second half of 2026 opens a second large indication.
3. Pipeline breadth and platform
Beyond the two lead programs, Edgewise carries earlier candidates including EDG-003 and EDG-15400, extending its muscle-modulation platform across additional muscular dystrophy and cardiac indications. This gives multiple shots on goal, though the earlier assets contribute little near-term value compared with sevasemten and EDG-7500.
4. Balance-sheet strength
With roughly $499.6 million in cash and marketable securities as of March 31, 2026 and a quarterly operating burn in the $50 million range, Edgewise has a multi-year runway that can carry it through its key Becker and HCM readouts without an immediate need to raise capital. That cushion reduces near-term financing dilution risk relative to many pre-revenue peers.
What are the risks to Edgewise Therapeutics, Inc. (EWTX)?
As a pre-revenue clinical-stage biotech, Edgewise has no approved products and its value depends on binary trial outcomes that can move the stock violently in either direction. A disappointing GRAND CANYON readout or a regulatory setback for sevasemten would remove a large share of the company's expected value. The HCM field is crowded with better-capitalized rivals, so EDG-7500 must show a genuinely differentiated safety and efficacy profile to matter commercially. The company continues to post net losses and will eventually need commercial success or further financing, which could dilute shareholders, and rare-disease trials carry meaningful enrollment, endpoint, and approval uncertainty.
How is Edgewise Therapeutics, Inc. (EWTX) valued? (approximate, MARCH 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Edgewise Therapeutics, Inc.'s investor relations page or your broker.
- Product revenue: ~$0 (pre-commercial)
- Cash & marketable securities: ~$499.6M
- Net loss (Q1 2026): ~$49.0M
- Net loss per share (Q1 2026): ~$0.46
- R&D expense (Q1 2026): ~$42.7M
- Market cap (mid-2026): ~$4.5B
- Shares outstanding: ~107.6M
Edgewise generates no product revenue, so traditional valuation multiples do not apply and the stock trades on the expected value of its pipeline. The roughly $499.6 million cash position against a quarterly burn near $50 million supports a runway of several years past the key Becker readout. The multi-billion-dollar market capitalization reflects investor expectations for sevasemten and EDG-7500 rather than any current financial performance.
Who competes with Edgewise Therapeutics, Inc. (EWTX)?
Cardiac myosin and sarcomere modulators
In hypertrophic cardiomyopathy, EDG-7500 competes against Bristol Myers Squibb's approved Camzyos (mavacamten) and Cytokinetics' aficamten, both first-generation cardiac myosin inhibitors with far larger commercial and financial resources. Edgewise's pitch is a differentiated mechanism that aims to avoid the ejection-fraction reductions seen with those drugs.
Muscular dystrophy therapeutics
In Duchenne and Becker muscular dystrophy, Edgewise operates alongside companies such as Sarepta Therapeutics, PTC Therapeutics, and Solid Biosciences, which pursue gene therapy, exon-skipping, and other approaches. Sevasemten's small-molecule muscle-protection mechanism is distinct, and Becker in particular currently lacks an approved disease-modifying therapy.
Broader clinical-stage rare-disease biotech
More generally EWTX competes for investor capital and clinical talent with the wider universe of pre-revenue rare-disease and cardiovascular biotechs, where scarce specialist funding flows toward the programs with the strongest data and clearest regulatory path.
How to invest in Edgewise Therapeutics, Inc. (EWTX)
There are three common ways to get EWTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so EWTX sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where EWTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Edgewise Therapeutics, Inc. (EWTX)
Edgewise is a cash-rich, pre-revenue clinical biotech whose story lives and dies on late-stage trial data, not earnings.
More on Edgewise Therapeutics, Inc. (EWTX)
Whether EWTX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EWTX a buy?, and where the stock could go from here in the EWTX stock forecast.
For income investors, whether EWTX pays a dividend and how the payout looks is covered in does EWTX pay a dividend?
Build a basket around EWTX with Walnut
Use Edgewise Therapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Edgewise Therapeutics do?
+
Edgewise is a clinical-stage biopharmaceutical company developing orally administered small molecules that target muscle. Its programs address rare neuromuscular diseases such as Becker and Duchenne muscular dystrophy and serious cardiac conditions like hypertrophic cardiomyopathy.
Is EWTX profitable?
+
No. Edgewise is pre-commercial with no approved products and generates no product revenue. It reported a net loss of roughly $49.0 million in the first quarter of 2026, funded by its cash and marketable securities.
What is sevasemten?
+
Sevasemten (formerly EDG-5506) is Edgewise's lead candidate, a skeletal myosin inhibitor being studied to slow muscle degeneration in Becker and Duchenne muscular dystrophy. Its pivotal GRAND CANYON top-line results in Becker are expected in the fourth quarter of 2026.
What is EDG-7500?
+
EDG-7500 is Edgewise's cardiac sarcomere modulator for hypertrophic cardiomyopathy. It posted positive 12-week Phase 2 CIRRUS-HCM data in mid-2026, and the company has targeted the start of a Phase 3 program for the second half of 2026.
How much cash does Edgewise have?
+
Edgewise reported approximately $499.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026. Against a quarterly operating burn near $50 million, that supports a multi-year runway through its key trial readouts.
Does EWTX pay a dividend?
+
No. Like most clinical-stage biotechs, Edgewise pays no dividend and reinvests its capital into research and development. Any cash it holds is directed toward advancing its pipeline rather than returning money to shareholders.
Why is EWTX considered a high-risk stock?
+
The company's value depends heavily on binary clinical trial outcomes and regulatory decisions rather than current earnings. A single disappointing readout, such as the GRAND CANYON Becker result, can move the share price sharply, which is common for pre-revenue biotech.
Who competes with Edgewise?
+
In hypertrophic cardiomyopathy it competes with Bristol Myers Squibb's Camzyos and Cytokinetics' aficamten. In muscular dystrophy it operates alongside firms like Sarepta Therapeutics, PTC Therapeutics, and Solid Biosciences, which use different therapeutic approaches.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Edgewise Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.